Diagnostic implication of change in b-type natriuretic peptide (BNP) for prediction of subsequent target lesion revascularization following silorimus-eluting stent deployment

International Journal of Cardiology

Volumn 168, Issue 2, 2013, Pages 1429-1434

  Hasumi, Eriko ^a   Iwata, Hiroshi ^a   Kohro, Takahide ^a   Manabe, Ichiro ^a   Kinugawa, Koichiro ^a   Morisaki, Naho ^b   Ando, Jiro ^a   Sawaki, Daigo ^a   Takahashi, Masao ^a   Fujita, Hideo ^a   Yamashita, Hiroshi ^a   Ako, Junya ^c   Hirata, Yasunobu ^a   Komuro, Issei ^a   Nagai, Ryozo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Biomarker; Drug eluting stent; Plasma BNP; Restenosis

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RAPAMYCIN; TICLOPIDINE; TOLL LIKE RECEPTOR;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIASTOLIC BLOOD PRESSURE; DRUG ELUTING STENT; DYSLIPIDEMIA; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROPENSITY SCORE; RECEIVER OPERATING CHARACTERISTIC; RESTENOSIS; RISK FACTOR; SMOKING HABIT;

BIOMARKER; DRUG-ELUTING STENT; PLASMA BNP; RESTENOSIS;

AGED; BIOLOGICAL MARKERS; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; NATRIURETIC PEPTIDE, BRAIN; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SIROLIMUS;

EID: 84885309602     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.12.046     Document Type: Article

References (29)

1. de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of b-type natriuretic peptide In patientswith acute coronary syndromes. N Engl J Med 2001;345:1014-21.
2. Omland T, Persson A, Ng L, et al. N-terminal pro-b-type natriuretic peptide and long-term mortality In acute coronary syndromes. Circulation 2002;106:2913-8.
3. Lindahl B, Lindback J, Jernberg T, et al. Serial analyses of n-terminal pro-b-type natriuretic peptide In patients with non-ST-segment elevation acute coronary syndromes: a fragmin and fast revascularisation during In stability In coronary artery disease (frisc)-ii substudy. J Am Coll Cardiol 2005;45:533-41.
4. Omland T, Richards AM, Wergeland R, Vik-Mo H. B-type natriuretic peptide and long-term survival In patients with stable coronary artery disease. Am J Cardiol 2005;95:24-8.
5. Omland T, Sabatine MS, Jablonski KA, et al. Prognostic value of b-type natriuretic peptides In patients with stable coronary artery disease: the peace trial. J Am Coll Cardiol 2007;50:205-14.
6. Bibbins-Domingo K, Ansari M, Schiller NB, Massie B, Whooley MA. B-type natriuretic peptide and Ischemia In patients with stable coronary disease: data from the heart and soul study. Circulation 2003;108:2987-92.
7. Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial Hypertension: the task force for the management of arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87.
8. Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease In the adult -2009 recommendations. Can J Cardiol 2009;25:567-79.
9. Nathan DM. International expert committee report on the role of the a1c assay In the diagnosis of diabetes. diabetes Care 2009;32:1327-34.
10. Arroyo-Espliguero R, Avanzas P, Cosin-Sales J, Aldama G, Pizzi C, Kaski JC. C-reactive protein elevation and disease activity In patients with coronary artery disease. Eur Heart J 2004;25:401-8.
11. Smith Jr SC, Feldman TE, Hirshfeld Jr JW, et al. ACC/AHA/SCAi 2005 Guideline Update for Percutaneous Coronary Intervention-Summary Article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAi Writing Committee to update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006;113:156-75.
12. D'Agostino Jr RB. Propensity score methods for bias reduction In the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-81.
13. Parsons L. Reducing bias In a propensity score matched-pair sample using greedy matching techniques. The Twenty-Sixth Annual SAS Users Group International Conference; 2004. p. 214-26.
14. Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-stent restenosis In the drug-eluting stent era. J Am Coll Cardiol 2010;56:1897-907.
15. Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes In patients presenting without persistent st-segment elevation. Eur Heart J 2002;23: 1809-40.
16. Fraker Jr TD, Fihn SD, Gibbons RJ, et al. 2007 Chronic Angina Focused Update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines writing group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. Circulation 2007;116:2762-72.
17. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (committee on the management of patients with chronic stable angina). Circulation 2003;107:149-58.
18. Deanfield JE, Maseri A, Selwyn AP, et al. Myocardial Ischaemia during daily life In patients with stable angina: Its relation to symptoms and heart rate changes. Lancet 1983;2:753-8.
19. Aronow WS, Epstein S. Usefulness of silent myocardial Ischemia detected by ambulatory electrocardiographic monitoring In predicting new coronary events In elderly patients. Am J Cardiol 1988;62:1295-6.
20. Valensi P, Sachs RN, Harfouche B, et al. Predictive value of cardiac autonomic neuropathy In diabetic patients with or without silent myocardial Ischemia. diabetes Care 2001;24:339-43.
21. Conlon PJ, Krucoff MW, Minda S, Schumm D, Schwab SJ. Incidence and long-term significance of transient ST segment deviation In hemodialysis patients. Clin Nephrol 1998;49:236-9.
22. Cohn PF, Fox KM, Daly C. Silentmyocardial Ischemia. Circulation 2003;108:1263-77.
23. Diamond GA, Forrester JS. analysis of probability as an aid In the clinical diagnosis of coronary-artery disease. N Engl J Med 1979;300:1350-8.
24. Coma-Canella I, Daza NS, Orbe LC. Detection of restenosis with dobutamine stress test after coronary angioplasty. Am Heart J 1992;124:1196-204.
25. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemicalmarker of high left ventricular end-diastolic pressure In patients with symptomatic left ventricular dysfunction. Am Heart J 1998;135:825-32.
26. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system In chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration In patients with chronic symptomatic left ventricular dysfunction. Circulation 1997;96:509-16.
27. Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-b-type natriuretic peptide and long-term mortality In stable coronary heart disease. N Engl J Med 2005;352:666-75.
28. Hong SN, Ahn Y, Yoon NS, et al. Usefulness of serum n-terminal pro-brain natriuretic peptide to predict In-stent restenosis In patients with preserved left ventricular function and normal troponin I levels. Am J Cardiol 2007;99:1051-4.
29. Schirger JA, Grantham JA, Kullo IJ, et al. Vascular actions of brain natriuretic peptide: modulation by atherosclerosis and neutral endopeptidase Inhibition. J Am Coll Cardiol 2000;35:796-801.